Cargando…

Microbial biotransformation to obtain stilbene methylglucoside with GPR119 agonistic activity

INTRODUCTION: Limitation of pharmaceutical application of resveratrol (RSV) and piceatannol (PIC) continue to exist, there is a need to obtain the superior analogs of two stilbenes with promoted activity, stability, and bioavailability. Microbial transformation has been suggested as a common and eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Yu, Huan, Yi, Chen, Jing-Jing, Chen, Tian-Jiao, Lei, Lei, Yang, Jin-Ling, Shen, Zhu-Fang, Gong, Ting, Zhu, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081513/
https://www.ncbi.nlm.nih.gov/pubmed/37032867
http://dx.doi.org/10.3389/fmicb.2023.1148513
_version_ 1785021139829915648
author Peng, Yu
Huan, Yi
Chen, Jing-Jing
Chen, Tian-Jiao
Lei, Lei
Yang, Jin-Ling
Shen, Zhu-Fang
Gong, Ting
Zhu, Ping
author_facet Peng, Yu
Huan, Yi
Chen, Jing-Jing
Chen, Tian-Jiao
Lei, Lei
Yang, Jin-Ling
Shen, Zhu-Fang
Gong, Ting
Zhu, Ping
author_sort Peng, Yu
collection PubMed
description INTRODUCTION: Limitation of pharmaceutical application of resveratrol (RSV) and piceatannol (PIC) continue to exist, there is a need to obtain the superior analogs of two stilbenes with promoted activity, stability, and bioavailability. Microbial transformation has been suggested as a common and efficient strategy to solve the above problems. METHODS: In this study, Beauveria bassiana was selected to transform RSV and PIC. LC-MS and NMR spectroscopies were used to analyze the transformed products and identify their structures. The biological activities of these metabolites were evaluated in vitro with GPR119 agonist and insulin secretion assays. Single factor tests were employed to optimize the biotransformation condition. RESULTS: Three new methylglucosylated derivatives of PIC (1–3) and two known RSV methylglucosides (4 and 5) were isolated and characterized from the fermentation broth. Among them, 1 not only showed moderate GPR119 agonistic activity with 65.9%, but also promoted insulin secretion level significantly (12.94 ng/mg protein/hour) at 1 μM. After optimization of fermentation conditions, the yield of 1 reached 45.53%, which was increased by 4.2-fold compared with the control. DISCUSSION: Our work presents that 3-O-MG PIC (1), obtained by microbial transformation, is an effective and safer ligand targeting GPR119, which lays a foundation for the anti-diabetic drug design in the future.
format Online
Article
Text
id pubmed-10081513
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100815132023-04-08 Microbial biotransformation to obtain stilbene methylglucoside with GPR119 agonistic activity Peng, Yu Huan, Yi Chen, Jing-Jing Chen, Tian-Jiao Lei, Lei Yang, Jin-Ling Shen, Zhu-Fang Gong, Ting Zhu, Ping Front Microbiol Microbiology INTRODUCTION: Limitation of pharmaceutical application of resveratrol (RSV) and piceatannol (PIC) continue to exist, there is a need to obtain the superior analogs of two stilbenes with promoted activity, stability, and bioavailability. Microbial transformation has been suggested as a common and efficient strategy to solve the above problems. METHODS: In this study, Beauveria bassiana was selected to transform RSV and PIC. LC-MS and NMR spectroscopies were used to analyze the transformed products and identify their structures. The biological activities of these metabolites were evaluated in vitro with GPR119 agonist and insulin secretion assays. Single factor tests were employed to optimize the biotransformation condition. RESULTS: Three new methylglucosylated derivatives of PIC (1–3) and two known RSV methylglucosides (4 and 5) were isolated and characterized from the fermentation broth. Among them, 1 not only showed moderate GPR119 agonistic activity with 65.9%, but also promoted insulin secretion level significantly (12.94 ng/mg protein/hour) at 1 μM. After optimization of fermentation conditions, the yield of 1 reached 45.53%, which was increased by 4.2-fold compared with the control. DISCUSSION: Our work presents that 3-O-MG PIC (1), obtained by microbial transformation, is an effective and safer ligand targeting GPR119, which lays a foundation for the anti-diabetic drug design in the future. Frontiers Media S.A. 2023-03-22 /pmc/articles/PMC10081513/ /pubmed/37032867 http://dx.doi.org/10.3389/fmicb.2023.1148513 Text en Copyright © 2023 Peng, Huan, Chen, Chen, Lei, Yang, Shen, Gong and Zhu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Peng, Yu
Huan, Yi
Chen, Jing-Jing
Chen, Tian-Jiao
Lei, Lei
Yang, Jin-Ling
Shen, Zhu-Fang
Gong, Ting
Zhu, Ping
Microbial biotransformation to obtain stilbene methylglucoside with GPR119 agonistic activity
title Microbial biotransformation to obtain stilbene methylglucoside with GPR119 agonistic activity
title_full Microbial biotransformation to obtain stilbene methylglucoside with GPR119 agonistic activity
title_fullStr Microbial biotransformation to obtain stilbene methylglucoside with GPR119 agonistic activity
title_full_unstemmed Microbial biotransformation to obtain stilbene methylglucoside with GPR119 agonistic activity
title_short Microbial biotransformation to obtain stilbene methylglucoside with GPR119 agonistic activity
title_sort microbial biotransformation to obtain stilbene methylglucoside with gpr119 agonistic activity
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081513/
https://www.ncbi.nlm.nih.gov/pubmed/37032867
http://dx.doi.org/10.3389/fmicb.2023.1148513
work_keys_str_mv AT pengyu microbialbiotransformationtoobtainstilbenemethylglucosidewithgpr119agonisticactivity
AT huanyi microbialbiotransformationtoobtainstilbenemethylglucosidewithgpr119agonisticactivity
AT chenjingjing microbialbiotransformationtoobtainstilbenemethylglucosidewithgpr119agonisticactivity
AT chentianjiao microbialbiotransformationtoobtainstilbenemethylglucosidewithgpr119agonisticactivity
AT leilei microbialbiotransformationtoobtainstilbenemethylglucosidewithgpr119agonisticactivity
AT yangjinling microbialbiotransformationtoobtainstilbenemethylglucosidewithgpr119agonisticactivity
AT shenzhufang microbialbiotransformationtoobtainstilbenemethylglucosidewithgpr119agonisticactivity
AT gongting microbialbiotransformationtoobtainstilbenemethylglucosidewithgpr119agonisticactivity
AT zhuping microbialbiotransformationtoobtainstilbenemethylglucosidewithgpr119agonisticactivity